Early and Mid-Term Outcomes of Primary Repair After Atrioventricular Canal Defect: A Single-Center Eight-Year Experience.
atrioventricular septal defect
down syndrome
mortality
surgical outcomes
surgical repair
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
accepted:
15
09
2023
medline:
17
10
2023
pubmed:
17
10
2023
entrez:
17
10
2023
Statut:
epublish
Résumé
Surgical repair techniques and management of patients with atrioventricular septal defect (AVSD) have progressed over the last few decades. Early and definitive interventions have become the choice of treatment for these patients. Based on this background, we aimed to review the early and mid-term outcomes of primary AVSD repair. A total of 53 patients with a mean age of 3.45 ± 5.67 years underwent definitive repair for AVSD between January 2014 and June 2021. The clinical data including age, type of defect, associated co-anomalies, symptoms, pulmonary hypertension, etc. were collected and assessed retrospectively. Mitral regurgitation (MR) as a clinical outcome was assessed at 0, 1, 2, and 5 years. Among the recruited patients, 35 (66.1%) were male and 18 (33.9%) were female. Of 53 patients, repair for the complete defect was done in 38 (71.69%) patients, repair for intermediate/partial defect was done in 15 (23.1%) patients, and one patient underwent repair for incomplete type. Other associated co-anomalies were anterior mitral leaflet (12 (22.6%)), atrial and ventricular septal defect (VSD) (30 (56.6%)), and patent ductus arteriosus (PDA) (11 (20.8%)). Different procedures for surgical repair included patch closure, cleft repair, and polytetrafluoroethylene (PTFE) VSD closure. After repair, the mean follow-up period was 46.73 ± 27.37 months. Overall mortality was 3.78% (2/53), and two patients underwent reintervention due to symptomatic severe MR. A definitive and timely correction of AVSD shows satisfactory early and mid-term results.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Surgical repair techniques and management of patients with atrioventricular septal defect (AVSD) have progressed over the last few decades. Early and definitive interventions have become the choice of treatment for these patients. Based on this background, we aimed to review the early and mid-term outcomes of primary AVSD repair.
METHODS
METHODS
A total of 53 patients with a mean age of 3.45 ± 5.67 years underwent definitive repair for AVSD between January 2014 and June 2021. The clinical data including age, type of defect, associated co-anomalies, symptoms, pulmonary hypertension, etc. were collected and assessed retrospectively. Mitral regurgitation (MR) as a clinical outcome was assessed at 0, 1, 2, and 5 years.
RESULTS
RESULTS
Among the recruited patients, 35 (66.1%) were male and 18 (33.9%) were female. Of 53 patients, repair for the complete defect was done in 38 (71.69%) patients, repair for intermediate/partial defect was done in 15 (23.1%) patients, and one patient underwent repair for incomplete type. Other associated co-anomalies were anterior mitral leaflet (12 (22.6%)), atrial and ventricular septal defect (VSD) (30 (56.6%)), and patent ductus arteriosus (PDA) (11 (20.8%)). Different procedures for surgical repair included patch closure, cleft repair, and polytetrafluoroethylene (PTFE) VSD closure. After repair, the mean follow-up period was 46.73 ± 27.37 months. Overall mortality was 3.78% (2/53), and two patients underwent reintervention due to symptomatic severe MR.
CONCLUSIONS
CONCLUSIONS
A definitive and timely correction of AVSD shows satisfactory early and mid-term results.
Identifiants
pubmed: 37846269
doi: 10.7759/cureus.45304
pmc: PMC10576971
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e45304Informations de copyright
Copyright © 2023, Kumar et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Ann Thorac Surg. 1998 Mar;65(3):754-9; discussion 759-60
pubmed: 9527207
J Thorac Cardiovasc Surg. 2015 Aug;150(2):369-74
pubmed: 26048271
Ann Thorac Surg. 1986 Jan;41(1):4-21
pubmed: 3510593
Genet Med. 2001 Mar-Apr;3(2):91-101
pubmed: 11280955
J Thorac Cardiovasc Surg. 2014 Dec;148(6):2526-31
pubmed: 25125206
J Thorac Cardiovasc Surg. 2020 Mar;159(3):1014-1025.e8
pubmed: 31590953
Heart. 2006 Dec;92(12):1879-85
pubmed: 17105897
Orphanet J Rare Dis. 2006 Apr 05;1:8
pubmed: 16722604
Ann Thorac Surg. 2006 Nov;82(5):1598-601; discussion 1602
pubmed: 17062212
Eur J Med Genet. 2018 Sep;61(9):546-550
pubmed: 29753092
Ann Thorac Surg. 2000 Apr;69(4 Suppl):S36-43
pubmed: 10798414
Eur J Cardiothorac Surg. 2008 Oct;34(4):745-50
pubmed: 18693030
J Med Liban. 2010 Jan-Mar;58(1):3-7
pubmed: 20358852